文献速递真菌感染细菌感染、耐药与抗菌药物

接受伏立康唑与泊沙康唑预防的高危血液病患者突破性侵袭性真菌感染:一项系统综述

Breakthrough Invasive Fungal Infections in Patients With High-Risk Hematological Disorders Receiving Voriconazole and Posaconazole Prophylaxis: A Systematic Review.
PubMed 文献 · Clin Infect Dis · 2024-01-01

该系统综述按PRISMA指南检索文献(最后检索日期2023年4月19日),评估5293项研究并纳入300项提取数据,共描述1076例伏立康唑(42.5%)或泊沙康唑(57.5%)预防下的突破性侵袭性真菌感染。最常见病原为曲霉(40%)、毛霉目(20%)、念珠菌(18%)和镰刀菌(9%);31%病例存在确定、推定或可能的抗真菌耐药,治疗药物监测90例中32例(36%)唑类药物浓度低于治疗水平,117例报告感染相关死亡,达35%。

要点

  • 突破性感染以曲霉(40%)、毛霉目(20%)、念珠菌(18%)、镰刀菌(9%)为主。
  • 伏立康唑预防下毛霉目更常见,泊沙康唑预防下曲霉与镰刀菌更常见。
  • 31%病例存在耐药;治疗药物监测90例中32例(36%)唑类浓度低于治疗水平。

核心结论

  • 作者系统综述认为,最常见的突破性侵袭性真菌感染为曲霉病、毛霉病、念珠菌病和镰刀菌病;抗真菌耐药仅能解释少数病例;预防药物浓度低于治疗水平常见但罕有报告;需前瞻性研究以更好理解这些感染并确立最佳管理。

研究设计与样本

  • 按PRISMA指南开展系统综述;检索策略最后执行于2023年4月19日;评估5293项研究,纳入300项提取数据,描述1076例突破性侵袭性真菌感染。

主要发现

  • 1076例突破性侵袭性真菌感染发生于伏立康唑(42.5%)或泊沙康唑(57.5%)预防下。
  • 最常见病原为曲霉(40%)、毛霉目(20%)、念珠菌(18%)和镰刀菌(9%)。
  • 毛霉目在伏立康唑相关病例中更常见,曲霉与镰刀菌在泊沙康唑相关病例中更常见。
  • 31%病例存在确定、推定或可能的抗真菌耐药;治疗药物监测显示90例中32例(36%)唑类药物浓度低于治疗水平。
  • 117例报告感染相关死亡,达35%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Primary antifungal prophylaxis with mold-active azoles is used to prevent invasive fungal infections in patients with high-risk hematological disorders; however, breakthrough infections occur, and the reasons for treatment failure are still not fully understood. To help inform clinical decisions, we sought to define microbiological, clinical, and pharmacological characteristics of proven and probable breakthrough invasive fungal infections (bIFIs) in patients with high-risk hematological disorders receiving voriconazole or posaconazole prophylaxis. METHODS: We performed a systematic review of the literature following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The search strategy was last conducted on 19 April 2023. RESULTS: We assessed 5293 studies for eligibility, and 300 were selected for data extraction. These studies described 1076 cases of bIFIs occurring under voriconazole (42.5%) or posaconazole (57.5%). The most commonly found pathogens were Aspergillus (40%), Mucorales (20%), Candida (18%), and Fusarium (9%) species. Mucorales were more frequent among voriconazole-emerging cases, whereas Aspergillus and Fusarium were more prevalent among posaconazole-emerging cases. Definitive, putative, or probable antifungal resistance was found in 31% of cases. Therapeutic drug monitoring showed subtherapeutic azole concentration in 32 of 90 (36%) cases. Infection-related mortality was reported in 117 cases and reached 35%. CONCLUSIONS: In our systemic review, the most common bIFIs were aspergillosis, mucormycosis, candidiasis, and fusariosis. Antifungal resistance explains only a minority of cases. Subtherapeutic prophylaxis was frequent but rarely reported. Prospective studies are needed to better understand these infections and to establish optimal management.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Boutin CA, Durocher F, Beauchemin S, et al. Breakthrough Invasive Fungal Infections in Patients With High-Risk Hematological Disorders Receiving Voriconazole and Posaconazole Prophylaxis: A Systematic Review. Clin Infect Dis. 2024. PMID: 38752732. doi:10.1093/cid/ciae203

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。